Marina Barguil Macêdo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Marina Barguil Macêdo has a total of 80 co-authors. Here are the top co-authors by number of shared publications:
Andreas Jönsen
Department of Clinical Sciences, Rheumatology Lund University, Skåne University Hospital Lund Sweden
2 shared publicationsChristian Lood
Division of Rheumatology University of Washington Seattle Washington USA
2 shared publicationsDiogo Souza Domiciano
Faculdade de Medicina (FMUSP), Universidade de Sao Paulo, Av. Dr. Arnaldo, 455, 3º andar, sala 3193, Cerqueira César, São Paulo, SP, 01246-903, Brazil
2 shared publicationsIva Gunnarsson
Division of Rheumatology, Department of Medicine Solna Karolinska Institutet, Karolinska University Hospital Stockholm Sweden
2 shared publications- José Machado Moita Neto
Federal University of Piauí (UFPI), Brazil
2 shared publications Ricardo Fuller
2 shared publications
Latest Publications
- 23 May 2025
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 64 (9) , 5096-5100
Anti-mitochondrial antibodies as markers of disease activity in childhood-onset systemic lupus erythematosus: a longitudinal cohort study
Objectives: Mitochondria are prominent antigenic sources, capable of triggering IFN-induced inflammatory pathways in SLE. Recent studies suggest presence of AMA in LN patients with adult-onset SLE. Whether AMA reflect disease activity in childhood-onset SLE (cSLE) remains unexplored. Here, we present inaugural data on the potential utility of AMA as a biomarker in cSLE. Methods: Human mitochondria were incubated with serum, and IgG, IgM and IgA binding assessed by flow cytometry. Sera were obtained prospectively from 29 cSLE patients, at two different timepoints (TP), the first (TP-1) representing a state of active disease (SLEDAI ≥4), and the second (TP-2), of clinically quiescent disease (SLEDAI ≤4). IFNα2 serum levels were assessed by single-molecule array. Results: Median age at disease diagnosis was 14.9 ± 3.6 years. Median SLEDAI and prednisone dose were 9.5 and 0.43 mg/kg/day at TP-1, and 2 and 0.14 mg/kg/day at TP-2. Median time interval between TP-1 and TP-2 was of 6 ± 3.7 months. AMA-IgG decreased between TP-1 and TP-2 (P = 0.0426), and correlated positively with SLEDAI (ρ = 0.41, P = 0.026) and anti-dsDNA (ρ = 0.66, P = 0.0001) at TP-1. AMA-IgM oscillated according to disease activity (P = 0.0065), while AMA-IgA remained stable. AMA-IgG and -IgM correlated with IFNα2 levels (ρ = 0.729, P < 0.0001, and ρ = 0.631, P = 0.001, respectively) during active disease. Conclusion: AMA-IgG emerges as a promising biomarker of disease activity in cSLE, and its increase is in alignment with elevated IFNα2 expression.
- 23 May 2025
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 64 (9) , 5096-5100
Anti-mitochondrial antibodies as markers of disease activity in childhood-onset systemic lupus erythematosus: a longitudinal cohort study
Objectives: Mitochondria are prominent antigenic sources, capable of triggering IFN-induced inflammatory pathways in SLE. Recent studies suggest presence of AMA in LN patients with adult-onset SLE. Whether AMA reflect disease activity in childhood-onset SLE (cSLE) remains unexplored. Here, we present inaugural data on the potential utility of AMA as a biomarker in cSLE. Methods: Human mitochondria were incubated with serum, and IgG, IgM and IgA binding assessed by flow cytometry. Sera were obtained prospectively from 29 cSLE patients, at two different timepoints (TP), the first (TP-1) representing a state of active disease (SLEDAI ≥4), and the second (TP-2), of clinically quiescent disease (SLEDAI ≤4). IFNα2 serum levels were assessed by single-molecule array. Results: Median age at disease diagnosis was 14.9 ± 3.6 years. Median SLEDAI and prednisone dose were 9.5 and 0.43 mg/kg/day at TP-1, and 2 and 0.14 mg/kg/day at TP-2. Median time interval between TP-1 and TP-2 was of 6 ± 3.7 months. AMA-IgG decreased between TP-1 and TP-2 (P = 0.0426), and correlated positively with SLEDAI (ρ = 0.41, P = 0.026) and anti-dsDNA (ρ = 0.66, P = 0.0001) at TP-1. AMA-IgM oscillated according to disease activity (P = 0.0065), while AMA-IgA remained stable. AMA-IgG and -IgM correlated with IFNα2 levels (ρ = 0.729, P < 0.0001, and ρ = 0.631, P = 0.001, respectively) during active disease. Conclusion: AMA-IgG emerges as a promising biomarker of disease activity in cSLE, and its increase is in alignment with elevated IFNα2 expression.
- 19 May 2025
- Published by Wiley in British Journal of Haematology
- Vol. 207 (1) , 201-205
Anti‐ HSP90α IgG may protect against antiphospholipid syndrome in systemic lupus erythematosus by reducing platelet activation
Summary: Natural autoantibodies (NAAbs) are immunoglobulins generated in the absence of antigen provocation, with no inherent pathogenic effect, but instead involved in maintaining immune homeostasis. We aimed to evaluate the implication of immunoglobulin G (IgG) antibodies against heat shock protein 90α (HSP90α) in systemic lupus erythematosus (SLE) patients, focusing on how those NAAbs may interfere with the immunothrombosis process. Anti‐HSP90α IgG was measured by an enzyme‐linked immunosorbent assay in the plasma of 308 SLE individuals, paired with 308 healthy controls (HC). Validation was performed in another cohort, comprised of serum from 125 SLE and 77 HC. In an in vitro experiment, platelets were cultured with mitochondria (abundant sources of HSP90α) treated with anti‐HSP90α IgG, and the activation markers thrombospondin‐1 and platelet factor 4 were measured in the supernatant. Levels of anti‐HSP90α IgG were comparable in SLE and HC, but decreased in the SLE patients with secondary antiphospholipid syndrome (APS), both in the exploratory and the validation cohort ( p = 0.0265, and p = 0.0472 respectively). Mitochondria triggered platelet activation in a TLR2‐ and HSP90α‐dependent manner ( p = 0.0152 and p < 0.001 respectively). Anti‐HSP90α IgG emerges as a prominent NAAb‐modulating immunothrombosis in SLE and holds promise as a biomarker of APS risk in these patients.
- 19 May 2025
- Published by Wiley in British Journal of Haematology
- Vol. 207 (1) , 201-205
Anti‐ HSP90α IgG may protect against antiphospholipid syndrome in systemic lupus erythematosus by reducing platelet activation
Summary: Natural autoantibodies (NAAbs) are immunoglobulins generated in the absence of antigen provocation, with no inherent pathogenic effect, but instead involved in maintaining immune homeostasis. We aimed to evaluate the implication of immunoglobulin G (IgG) antibodies against heat shock protein 90α (HSP90α) in systemic lupus erythematosus (SLE) patients, focusing on how those NAAbs may interfere with the immunothrombosis process. Anti‐HSP90α IgG was measured by an enzyme‐linked immunosorbent assay in the plasma of 308 SLE individuals, paired with 308 healthy controls (HC). Validation was performed in another cohort, comprised of serum from 125 SLE and 77 HC. In an in vitro experiment, platelets were cultured with mitochondria (abundant sources of HSP90α) treated with anti‐HSP90α IgG, and the activation markers thrombospondin‐1 and platelet factor 4 were measured in the supernatant. Levels of anti‐HSP90α IgG were comparable in SLE and HC, but decreased in the SLE patients with secondary antiphospholipid syndrome (APS), both in the exploratory and the validation cohort ( p = 0.0265, and p = 0.0472 respectively). Mitochondria triggered platelet activation in a TLR2‐ and HSP90α‐dependent manner ( p = 0.0152 and p < 0.001 respectively). Anti‐HSP90α IgG emerges as a prominent NAAb‐modulating immunothrombosis in SLE and holds promise as a biomarker of APS risk in these patients.
- Open Access
- 14 January 2025
- Published by BMJ in Lupus Science & Medicine
- Vol. 12 (1) , e001418
Neutrophil gelatinase-associated lipocalin (NGAL) in lupus nephritis and beyond
Objectives: To study neutrophil gelatinase-associated lipocalin (NGAL) levels in peripheral blood in SLE, and to propose a mechanism by which neutrophils secrete NGAL on stimulation with immune complexes (IC). Methods: NGAL was measured by ELISA in two independent Swedish SLE cohorts acting as exploratory and validation cohort (n=124 and n=308, respectively), disease controls (n=38) and healthy controls (n=77). NGAL levels were measured in supernatant from IC-stimulated neutrophils in the presence or absence of a toll-like receptor 8 inhibitor (TLR8i). Results: In the exploratory cohort, serum levels of NGAL were increased in patients with SLE as compared with healthy controls (p=0.021), and associated with histological-proven membranoproliferative lupus nephritis (LN) (p=0.018). In the validation cohort, plasma levels of NGAL were elevated in patients with a history of LN (p=0.0048), as well as in patients with SLE with secondary antiphospholipid syndrome (APS) compared with those without (p=0.0022). In both cohorts, NGAL was able to discriminate patients with a creatinine clearance <60 mL/min (chronic kidney disease stage 3 or more) with high accuracy, with an area under the curve of 0.92 (p<0.0001) and 0.94 (p=0.0088), respectively. Neutrophils stimulated with IC secrete more NGAL, when compared with baseline, and this process was blocked by adding a TLR8i. Conclusion: Blood levels of NGAL are increased in patients with SLE with decreased kidney function, and in those with secondary APS. The mechanism behind NGAL increase in SLE may be related to TLR8 pathway activation by circulating RNA-containing IC.
- 14 January 2025
- Published by BMJ in Lupus Science & Medicine
- Vol. 12 (1) , e001418
Open AccessNeutrophil gelatinase-associated lipocalin (NGAL) in lupus nephritis and beyond
Objectives: To study neutrophil gelatinase-associated lipocalin (NGAL) levels in peripheral blood in SLE, and to propose a mechanism by which neutrophils secrete NGAL on stimulation with immune complexes (IC). Methods: NGAL was measured by ELISA in two independent Swedish SLE cohorts acting as exploratory and validation cohort (n=124 and n=308, respectively), disease controls (n=38) and healthy controls (n=77). NGAL levels were measured in supernatant from IC-stimulated neutrophils in the presence or absence of a toll-like receptor 8 inhibitor (TLR8i). Results: In the exploratory cohort, serum levels of NGAL were increased in patients with SLE as compared with healthy controls (p=0.021), and associated with histological-proven membranoproliferative lupus nephritis (LN) (p=0.018). In the validation cohort, plasma levels of NGAL were elevated in patients with a history of LN (p=0.0048), as well as in patients with SLE with secondary antiphospholipid syndrome (APS) compared with those without (p=0.0022). In both cohorts, NGAL was able to discriminate patients with a creatinine clearance <60 mL/min (chronic kidney disease stage 3 or more) with high accuracy, with an area under the curve of 0.92 (p<0.0001) and 0.94 (p=0.0088), respectively. Neutrophils stimulated with IC secrete more NGAL, when compared with baseline, and this process was blocked by adding a TLR8i. Conclusion: Blood levels of NGAL are increased in patients with SLE with decreased kidney function, and in those with secondary APS. The mechanism behind NGAL increase in SLE may be related to TLR8 pathway activation by circulating RNA-containing IC.
- 14 September 2022
- Published by Galenos Yayinevi in Eurasian Journal of Emergency Medicine
- Vol. 21 (3) , 222-224
Shouldering the Pain: Septic Sternoclavicular Arthritis Following Pericardiostomy in a Systemic Lupus Erythematosus Patient
- 14 September 2022
- Published by Galenos Yayinevi in Eurasian Journal of Emergency Medicine
- Vol. 21 (3) , 222-224
Shouldering the Pain: Septic Sternoclavicular Arthritis Following Pericardiostomy in a Systemic Lupus Erythematosus Patient
- 26 June 2022
- Published by Elsevier in European Journal of Vascular and Endovascular Surgery
- Vol. 64 (2-3) , 242
Thrombosis of Atypical Location at Lupus Onset
- 26 June 2022
- Published by Elsevier in European Journal of Vascular and Endovascular Surgery
- Vol. 64 (2-3) , 242
Thrombosis of Atypical Location at Lupus Onset
- 10 May 2022
- Published by Springer Nature in Internal and Emergency Medicine
- Vol. 17 (5) , 1559
Editorial Expression of Concern: Breaking the diagnosis: ankylosing spondylitis evidenced by cervical fracture following spine manipulation
- 10 May 2022
- Published by Springer Nature in Internal and Emergency Medicine
- Vol. 17 (5) , 1559
Editorial Expression of Concern: Breaking the diagnosis: ankylosing spondylitis evidenced by cervical fracture following spine manipulation
- 10 February 2022
- Published by Elsevier in Experimental Gerontology
- Vol. 161, 111734
Association between osteoarthritis and atherosclerosis: A systematic review and meta-analysis
- 10 February 2022
- Published by Elsevier in Experimental Gerontology
- Vol. 161, 111734
Association between osteoarthritis and atherosclerosis: A systematic review and meta-analysis
- 1 February 2022
- Published by Elsevier in Clinics and Research in Hepatology and Gastroenterology
- Vol. 46 (2) , 101823
A retracted diagnosis-when liver capsule retraction is not what it seems
- 1 February 2022
- Published by Elsevier in Clinics and Research in Hepatology and Gastroenterology
- Vol. 46 (2) , 101823
A retracted diagnosis-when liver capsule retraction is not what it seems
- 20 August 2021
- Published by Springer Nature in Internal and Emergency Medicine
- Vol. 17 (1) , 273-274
Breaking the diagnosis: ankylosing spondylitis evidenced by cervical fracture following spine manipulation
- 20 August 2021
- Published by Springer Nature in Internal and Emergency Medicine
- Vol. 17 (1) , 273-274
Breaking the diagnosis: ankylosing spondylitis evidenced by cervical fracture following spine manipulation